HopeStage
Back to all studies
CompletedNCT06115603

Cannabigerol compared with placebo for ADHD symptoms

About this titleRead the official source — NCT06115603
Medication studyAges 18–55United States
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 55 years.

Listed locations
FayettevilleSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: December 14, 2024
Recruitment status
Completed
Enrollment listed in the registry
76
Sponsor
University of Arkansas, Fayetteville
Sponsor type
University
Study type
Drug
Intervention type
Drug, Other
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 55 Years
Official registry ID
NCT06115603
Official title
Show the full official title

CBG and Attention: A Double-Blind, Randomized, Placebo-Controlled Trial Examining the Effects of Cannabigerol on Indicators of Attention-Deficit/Hyperactivity Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Fayetteville

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is University of Arkansas, Fayetteville, a university.

Did this study involve medication?

Yes. The study involved medication, including Cannabigerol.

Who was this study for?

Listed age limits: 18 years to 55 years.

Want to explore more studies?

Explore studies